Gaps in hepatocellular carcinoma surveillance in a United States cohort of insured patients with cirrhosis

References

• National Cancer Institute. Cancer stat facts: Liver and intrahepatic bile duct cancer. 2020. [cited 2020 July]. Available at: https://seer.cancer.gov/statfacts/html/livibd.html.
   Google Scholar
• Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017. JAMA Oncol. 2019;5(12):1749–1769.
   PubMed Web of Science ®Google Scholar
• Noone A, Howlader N, Krapcho M, et al. Seer cancer statistics review, 1975–2017. 2020. [cited 2020 July]. Available at: https://seer.cancer.gov/csr/1975_2017/.
   Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380.
   PubMed Web of Science ®Google Scholar
• Abd El Aziz MA, Facciorusso A, Nayfeh T, et al. Immune checkpoint inhibitors for unresectable hepatocellular carcinoma. Vaccines. 2020;8(4):616.
   PubMed Web of Science ®Google Scholar
• Covey AM. Hepatocellular carcinoma: updates to screening and diagnosis. J Natl Compr Canc Netw. 2018;16(5S):663–665.
   PubMed Web of Science ®Google Scholar
• Simmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 2017;45(1):169–177.
   PubMed Web of Science ®Google Scholar
• Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706–1718.e1701.
   PubMed Web of Science ®Google Scholar
• Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72(2):250–261.
   PubMed Web of Science ®Google Scholar
• Singal AG, Yopp ACS, Packer M, et al. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med. 2012;27(7):861–867.
   PubMed Web of Science ®Google Scholar
• Goldberg DS, Taddei TH, Serper M, et al. Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis. Hepatology. 2017;65(3):864–874.
   PubMed Web of Science ®Google Scholar
• Ahmed Mohammed HA, Yang JD, Giama NH, et al. Factors influencing surveillance for hepatocellular carcinoma in patients with liver cirrhosis. Liver Cancer. 2017;6(2):126–136.
   PubMed Web of Science ®Google Scholar
• Singal AG, Tiro J, Li X, et al. Hepatocellular carcinoma surveillance among patients with cirrhosis in a population-based integrated health care delivery system. J Clin Gastroenterol. 2017;51(7):650–655.
   PubMed Web of Science ®Google Scholar
• Tran SA, Le A, Zhao C, et al. Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis. BMJ Open Gastroenterol. 2018;5(1):e000192.
   PubMed Web of Science ®Google Scholar
• Wolf E, Rich NE, Marrero JA, et al. Utilization of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis. Hepatology. 2021;73(2):713–725.
   PubMed Web of Science ®Google Scholar
• Zhao C, Xing F, Yeo YH, et al. Only one-third of hepatocellular carcinoma cases are diagnosed via screening or surveillance: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2020;32(3):406–419.
   PubMed Web of Science ®Google Scholar
• Onyirioha K, Mittal S, Singal AG. Is hepatocellular carcinoma surveillance in high-risk populations effective? Hepat Oncol. 2020;7(3):HEP25.
   PubMed Web of Science ®Google Scholar
• Optum, Inc. Optum claims data. 2021. [cited 2021 July 27]. Available from: https://www.optum.com/business/solutions/life-sciences/real-world-data/claims-data.html.
   Google Scholar
• Whyte JL, Engel-Nitz NM, Teitelbaum A, et al. An evaluation of algorithms for identifying metastatic breast, lung, or colorectal cancer in administrative claims data. Med Care. 2015;53(7):e49-57–e57.
   PubMed Web of Science ®Google Scholar
• Eslam M, Sanyal AJ, George J. International consensus P. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.e1991.
   PubMed Web of Science ®Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682.
   PubMed Web of Science ®Google Scholar
• Clinical Classifications Software (CCS) for ICD-9-CM/ICD-10-CM. Agency for healthcare research and quality. Rockville (MD); 2020. Available from: https://www.hcup-us.ahrq.gov/tools_software.jsp
   Google Scholar
• Goldberg DS, Valderrama A, Kamalakar R, et al. Hepatocellular carcinoma surveillance among cirrhotic patients with commercial health insurance. J Clin Gastroenterol. 2016;50(3):258–265.
   PubMed Web of Science ®Google Scholar
• US Department of Labor, Bureau of Labor Statistics. National occupational employment and wage estimates. [cited April 2017]. Available from: https://www.bls.gov/oes/current/oes_nat.htm#00-0000.
   Google Scholar
• US Department of Labor. Minimum wage; 2017. Available from: https://www.dol.gov/agencies/whd/minimum-wage.
   Google Scholar
• Gaba RC, Kallwitz ER, Parvinian A, et al. Imaging surveillance and multidisciplinary review improves curative therapy access and survival in HCC patients. Ann Hepatol. 2013;12(5):766–773.
   PubMed Web of Science ®Google Scholar
• Kanwal F, Tapper EB, Ho C, et al. Development of quality measures in cirrhosis by the practice metrics committee of the American Association for the study of liver diseases. Hepatology. 2019;69(4):1787–1797.
   PubMed Web of Science ®Google Scholar
• Mellinger JL, Moser S, Welsh DE, et al. Access to subspecialty care and survival among patients with liver disease. Am J Gastroenterol. 2016;111(6):838–844.
   PubMed Web of Science ®Google Scholar
• Beste LA, Leipertz SL, Green PK, et al. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. Gastroenterology. 2015;149(6):1471–1482 e1475. quiz e1417-1478.
   PubMed Web of Science ®Google Scholar
• Beste LA, Harp BK, Blais RK, et al. Primary care providers report challenges to cirrhosis management and specialty care coordination. Dig Dis Sci. 2015;60(9):2628–2635.
   PubMed Web of Science ®Google Scholar
• Dalton-Fitzgerald E, Tiro J, Kandunoori P, et al. Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015;13(4):791–798 e791.
   PubMed Web of Science ®Google Scholar
• Simmons OL, Feng Y, Parikh ND, et al. Primary care provider practice patterns and barriers to hepatocellular carcinoma surveillance. Clin Gastroenterol Hepatol. 2019;17(4):766–773.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Rodgers A, Altus R, et al. Optimisation of hepatocellular carcinoma surveillance in patients with viral hepatitis: a quality improvement study. Intern Med J. 2013;43(7):772–777.
   PubMed Web of Science ®Google Scholar
• Rogal SS, Yakovchenko V, Gonzalez R, et al. The hepatic innovation team collaborative: a successful population-based approach to hepatocellular carcinoma surveillance. Cancers. 2021;13(9):2251.
   PubMed Web of Science ®Google Scholar
• Del Poggio P, Olmi S, Ciccarese F, et al. A training program for primary care physicians improves the effectiveness of ultrasound surveillance of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2015;27(9):1103–1108.
   PubMed Web of Science ®Google Scholar
• Beste LA, Ioannou GN, Yang Y, et al. Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder. Clin Gastroenterol Hepatol. 2015;13(1):172–179.
   PubMed Web of Science ®Google Scholar
• Singal AG, Reddy S, Radadiya Aka Patel H, et al. Multicenter randomized clinical trial of a mailed outreach strategy for hepatocellular carcinoma surveillance. Clin Gastroenterol Hepatol. 2021. DOI:10.1016/j.cgh.2021.12.014
   Web of Science ®Google Scholar
• Singal AG, Tiro JA, Murphy CC, et al. Patient-reported barriers are associated with receipt of hepatocellular carcinoma surveillance in a multicenter cohort of patients with cirrhosis. Clin Gastroenterol Hepatol. 2021;19(5):987–995.e1.
   PubMed Web of Science ®Google Scholar
• Beal EW, Gorji L, Volney J, et al. Provider- and system-level barriers to surveillance for hepatocellular carcinoma among patients with chronic liver disease. Abstract presented at: ASCO Annual Meeting, Chicago, IL; June 3-7, 2022. J Clin Oncol. 2022;40(4_suppl):404–404.
   Web of Science ®Google Scholar
• Yeo YH, Hwang J, Jeong D, et al. Surveillance of patients with cirrhosis remains suboptimal in the United States. J Hepatol. 2021;75(4):856–864.
   PubMed Web of Science ®Google Scholar
• Goldberg DS, Valderrama A, Kamalakar R, et al. Hepatocellular carcinoma surveillance rates in commercially insured patients with noncirrhotic chronic hepatitis B. J Viral Hepat. 2015;22(9):727–736.
   PubMed Web of Science ®Google Scholar
• Vu TM, Toribio W, Riazi F, et al. Increasing access to hepatitis C virus medications: a program model using patient navigators and specialty pharmacy to obtain prior authorization approval. JMCP. 2018;24(4):329–333.
   PubMed Web of Science ®Google Scholar
• Woolen SA, Singal AG, Davenport MS, et al. Patient preferences for hepatocellular carcinoma surveillance parameters. Clin Gastroenterol Hepatol. 2022;20(1):204–215.e6.
   PubMed Web of Science ®Google Scholar
• Chalasani NP, Ramasubramanian TS, Bhattacharya A, et al. A novel Blood-Based panel of methylated DNA and protein markers for detection of early-stage hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2021;19(12):2597–2605 e2594.
   PubMed Web of Science ®Google Scholar
• Singal AG, Haaland B, Parikh ND, et al. Comparison of a multitarget blood test to ultrasound and alpha-fetoprotein for hepatocellular carcinoma surveillance: results of a network meta-analysis. Hepatol Commun. 2022. DOI:10.1002/hep4.2045
   Web of Science ®Google Scholar
• Centers for Medicare and Medicaid Services. Clinical laboratory fee schedule. 2021. [cited 2021 Feb 24]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched.
   Google Scholar
• Maine Health Data Organization and Maine Quality Forum. Compare Maine health costs & quality. 2021. [cited 2021 Feb 24]. Available from: https://www.comparemaine.org/.
   Google Scholar
• Beal EW, Owen M, McNamara M, et al. Patient-, provider-, and system-level barriers to surveillance for hepatocellular carcinoma in high-risk patients in the USA: a scoping review. J Gastrointest Canc. 2022.
   PubMed Web of Science ®Google Scholar